Subtype
Gastroesophageal Junction Carcinoma
CI-CAN-00005404Explore in graph →
231 active trials9 approved drugs25 evidence items
- NCIt
- C203675
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005404Explore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER |
| 1 |
| Jul 8, 2024 |
| clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | unknown | Phase 2 | 19 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT04890392 | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 66 | China Medical University, ChinaOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03966118 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma(AIO-STO-0218) | unknown | Phase 2 | 59 | P. C. Thuss-PatienceOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer(MICADO) | unknown | Phase 2 | 51 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03837301 | Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) | unknown | Phase 2 | 88 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01504997 | Phase II Study for Robot Assisted Distal Gastrectomy(RADGphaseII) | unknown | Phase 2 | 23 | Shizuoka Cancer CenterOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01523015 | Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction | unknown | Phase 2 / Phase 3 | 100 | Medical University of LublinOTHER | 1 | Feb 5, 2013 | clinicaltrials |
| NCT01641783 | Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients | unknown | Phase 2 | 40 | Yanqiao ZhangOTHER | 0 | Jul 17, 2012 | clinicaltrials |
| NCT01552980 | Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma(mSOX) | unknown | Phase 2 | 30 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2012 | clinicaltrials |
| NCT01095120 | Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer | unknown | Phase 2 | 27 | Genta IncorporatedINDUSTRY | 2 | Mar 15, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jul 11, 2024source: clinicaltrials